Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy. Unfortunately, drugs that target it do not trigger especially strong anti-cancer immune responses. New research published in Advanced Science reveals a promising strategy that harnesses pre-existing antiviral immunity to boost anti-tumor responses.
Researchers engineered what they call a PD-L1-binding antigen presenter (PBAP) that functions as a molecular bridge between tumor cells and immune cells. The construct fuses a protein segment that specifically binds to tumor-expressed PD-L1 with a highly immunogenic viral antigen, called varicella-zoster virus glycoprotein E (gE).
Experiments in cells and mouse models demonstrated that PBAP effectively anchors to PD-L1 on tumor surfaces, thereby tagging cancer cells with a viral signature recognized by the immune system. The strategy holds significant potential because most adults carry high amounts of anti-gE antibodies resulting from prior vaccination or natural infection. These pre-existing antibodies recognize PBAP-decorated tumor cells and execute a dual function: they trigger natural killer cells into action while simultaneously binding to the PBAP-gE complexes on tumor surfaces. This redirection transforms virus-specific immune memory into precision anti-cancer weapons.
Importantly, this strategy can extend beyond viral antigens. As an example, the researchers created PBAP-HER2, which redirected HER2-targeting therapies to eliminate HER2-negative, PD-L1-positive tumor cells. This expands applicability to multiple tumor types, addressing unmet needs for hard-to-treat cancers lacking effective targeted therapies.
“This strategy represents a lower-cost, safer avenue for tumor immunotherapy,” remarked Fan Zou, PhD, Professor at Shenzhen University of Advanced Technology. “It opens a transformative pathway that repurposes the body's natural antiviral defenses for therapeutic gain, with significant promise for clinical translation.”
URL: https://onlinelibrary.wiley.com/doi/10.1002/advs.202519574
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
Advanced Science, part of the prestigious Wiley Advanced portfolio, is an open access interdisciplinary science journal publishing the best-in-class fundamental and applied research in materials science, physics, chemistry, medical and life sciences, and engineering. Our mission is to give top science the maximum accessibility through open access publishing.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.